Skip to content

Feasibility Study of Unified Protocol for Anxiety and Depressive Disorders

Feasibility Study of Unified Protocol for Anxiety and Depressive Disorders - Open label study of Unified Protocol for Emotional Disorders

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008322
Enrollment
15
Registered
2012-07-12
Start date
2012-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders, Depressive Disorders

Interventions

CBT (Unified Protocol)

Sponsors

National Center of Neurology and Psychiatry, National Center for Cognitive Behavior Therapy and Research
Lead Sponsor
National Disaster Medical Center
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Subjects with current DSM-IV Panic disorder with/without Agoraphobia, Agoraphobia without history of Panic Disorder, Specific Phobia, Social Phobia (Social Anxiety Disorder), Obsessive-Compulsive Disorder, Post-Traumatic Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder Not Otherwise Specified, Major Depressive Disorder, Depressive Disorder Not Otherwise Specified 2. HAM-D Anxiety Factor >= 7 3. Age 20 years or older, and 65 years or younger at screening. 4. Subjects who give full consent in the participation of the study

Exclusion criteria

Exclusion criteria: 1. No alcohol or substance use disorder in 6 months prior to the screening. 2. No history or concurrent manic or psychotic episode. 3. No other primary DSM-IV Axis I Disorders in six months prior to the screening. 4. No comorbid of antisocial personality disorder. 5. No serious suicidal ideation at screening. 6. Evidence of unable to participate half or more of the intervention phase. 7. No past treatment of CBT. 8. No structured psychotherapy (except supportive therapy) during the intervention. 9. No major cognitive deficits at screening. 10. No life-threatening, severe or unstable physical disorders at screening. 11. Other relevant reason decided by the investigators.

Design outcomes

Primary

MeasureTime frame
Severity of anxiety symptoms assessed by the SIGH-A (0 week vs 1 week after the completion of intervention)

Secondary

MeasureTime frame
1. Diagnoses assessed by the M.I.N.I. 2. Objective severity of depressive symptoms (GRID-HAM-D) 3. Subjective severity of depressive symptoms (BDI-II) 4. Quality of Life (EuroQol etc) 5. Subjective symptoms for primary diagnosis (self-report scale) 6. Emotion Regulation (ERQ) 7. Experienced Emotion (PANAS) 8. Drop Out rates 9. Adverse Events

Countries

Japan

Contacts

Public ContactNoriko Kato

National Center of Neurology and Psychiatry National Center for Cognitive Behavior Therapy and Research

norikokato@ncnp.go.jp042-341-2712(3605)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026